Add this result to my export selection Idebenone (Raxone®) recommended for use within NHS Wales for treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON) Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 17 March 2021 There are currently no other licensed medicines available for treatment of LHON and current clinical practice is limited to best supportive care. The recommendation for this ultra-orphan medicine... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Lurasidone (Latuda®) recommended as option for use within NHS Wales for treatment of schizophrenia in adults and adolescents aged 13 years and over Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 17 March 2021 Company suggests that this second-generation atypical antipsychotic may provide an additional treatment option for patients with schizophrenia, in particular patients for whom it is clinically... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Melatonin (Slenyto®) recommended as option for use within NHS Wales Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 17 March 2021 This is recommended for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Dupilumab (Dupixent®) recommended for restricted use within NHS Wales in children age 6 to 11 years Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 17 March 2021 This is recommended for the treatment of severe atopic dermatitis in children age 6 to 11 years who are candidates for systemic therapy and where existing systemic therapies are not advisable. Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Opicapone (Ongentys®) recommended as an option for restricted use within NHS Wales in patients with Parkinson's disease and end-of-dose motor fluctuations Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 17 March 2021 This is recommended for use as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors in patients who cannot be stabilised on those combinations and for use after failure of... Read Summary Type: Prescribing and Technical Information (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Shared Care Prescribing and Monitoring Guidance Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 24 February 2021 Good organisation of care across interface between primary and secondary/tertiary care is crucial in ensuring that patients receive high quality care. This document updates the principles of best... Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Prescribing Dilemmas: A Guide for Prescribers Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 25 February 2021 Updated document provides guidance for health professionals covering areas ranging from clinical responsibility, prescribing duration, foodstuffs, complementary medicine, erectile dysfunction, ... Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Best Practice Reminder: Avoid Nitrofurantoin in the Treatment of Pyelonephritis Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 25 February 2021 This reminder highlights that nitrofurantoin should not be used if there are symptoms of pyelonephritis (such as fever), because it will not achieve adequate levels in renal tissue. Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection AWMSG consults on draft guidance on the initial clinical management of adult smokers in secondary care Source: All Wales Medicines Strategy Group - AWMSG (Remove filter) Published by All Wales Medicines Strategy Group, 04 February 2021 This document aims to inform healthcare staff in NHS Wales about the use of NRT to manage nicotine withdrawal in adult smokers admitted to hospital. It covers initial assessment and prescribing, ... Read Summary Type: Medicines Current Awareness (Remove filter)